Feedback / Questions
ondansetron ultra-low dose (AD04) - Adial
https://www.globenewswire.com/news-release/2025/02/12/3025074/26135/en/Adial-Pharmaceuticals-Awarded-New-U-S-Patent-Covering-Genotype-Specific-Treatment-of-Opioid-Related-Disorders.html
Feb 12, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next